Two withdrawals of recently submitted initial public offering (IPO) filings by drug developers, plus a dearth of new filings this month, suggest that the outlook for biopharma IPOs remains cloudy, complicated by factors that include share price declines for some recent offerings and the ongoing war in Iran and the broader Middle East.
Invea Therapeutics, a developer of oral small molecule drugs fo...
The biopharma IPO market is navigating a complex landscape shaped by economic volatility, geopolitical tensions, and shifting investor sentiment. The withdrawals of Invea Therapeutics and Edison Oncology underscore the fragility of market conditions, while the mixed performance of recent IPOs—ranging from Veradermics' meteoric rise to Eikon Therapeutics' steep decline—highlights the sector's unpredictability. The broader biotech sector's volatility, reflected in the 4-8% drop in major ETFs, sugg...